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Abstract
Background: Cognitive behaviour therapy for insomnia (CBT-I) is a well-established treatment; however, the
evidence is largely limited to homogenous samples. Although emerging research has indicated that CBT-I is also
effective for comorbid insomnia, CBT-I has not been tested among a complex sample of older adults with
comorbid insomnia and depression. Furthermore, no study has explored whether modifying CBT-I to target
associated depressive symptoms could potentially enhance sleep and mood outcomes. Therefore, this study aims
to report a protocol designed to test whether an advanced form of CBT for insomnia and depression (CBT-I-D) is
more effective at reducing insomnia and depressive symptoms compared to a standard CBT-I and psychoeducation
control group (PCG) for older adults in a community mental health setting.
Methods/Design: We aim to recruit 150 older adults with comorbid insomnia who have presented to community
mental health services for depression. Eligible participants will be randomly allocated via block/cluster
randomisation to one of three group therapy conditions: CBT-I, CBT-I-D, or PCG. Participants who receive CBT-I will
only practice strategies designed to improve their sleep, whereas participants who receive CBT-I-D will practice
additional strategies designed to also improve their mood. This trial will implement a mixed-methods design
involving quantitative outcome measures and qualitative focus groups. The primary outcome measures are
insomnia and depression severity, and secondary outcomes are anxiety, hopelessness, beliefs about sleep, comorbid
sleep conditions, and health. Outcomes will be assessed at pre-intervention (week 0), post-intervention (week 8),
and 3-month follow-up (week 20).
Discussion: This CBT study protocol has been designed to address comorbid insomnia and depression for older
adults receiving community mental health services. The proposed trial will determine whether CBT-I is more
effective for older adults with comorbid insomnia and depression compared to a PCG. It will also establish whether
an advanced form of CBT-I-D generates greater reductions in insomnia and depression severity compared to
standard CBT-I. The results from the proposed trial are anticipated to have important clinical implications for older
adults, researchers, therapists, and community mental health services.
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Background
Leaders in the field of cognitive behaviour therapy for
insomnia (CBT-I) have suggested that this form of psy-
chological treatment needs to be tested in more diverse
samples and settings [8, 41, 71]. Promising research has
indicated that CBT-I is effective at treating comorbid or
secondary insomnia [17, 23, 35]; however, the effective-
ness of CBT-I has not been examined among a complex
sample of older adults receiving community mental
health services for depression.
Insomnia and depression are commonly co-occurring
conditions experienced by older adults [55]. Studies have
reported that up to 90 % of individuals with depression re-
port problems with comorbid insomnia [70]. Historically,
insomnia was believed to have been primarily a symptom
or natural consequence of depression [31]. More recent
evidence has demonstrated that insomnia often precedes
the onset of depression among older adults [48, 55] and
can serve as an influential risk factor for depressive relapse
[49]. Furthermore, studies have suggested that many of
the symptoms required for the diagnosis of depression
(for example, tiredness, amotivation, depressed mood,
hopelessness, and poor concentration) can be attributed
to increased levels of insomnia [31, 64]. Collectively, these
findings have led researchers to hypothesise that, in some
cases, the relation between insomnia and depression is
reciprocal, as the two disorders can aggravate and main-
tain each other [8, 32]. Therefore, insomnia becomes not
only a symptom of depression but can become an inde-
pendent dysfunctional process and a comorbid disorder
that can subsequently jeopardise depression treatment.
There is preliminary data that suggests CBT-I could
have a positive effect on comorbid depression (for
example, [28, 32, 72]). This body of research, however, is
still in its infancy and contains several significant limita-
tions that restrict the strength and generalisability of the
findings (for example, younger participants, small sample
sizes, homogenous groups, and no randomisation design
or comparison/control group). Therefore, constructing a
study protocol that investigates whether CBT-I is effective
for older adults who are engaged with a mental health
service for depression would significantly contribute to
this body of literature.
No CBT-I trial has specifically investigated whether
additional therapeutic modifications need to be considered
when treating depression among older adults. Researchers
have suggested this is an important area of future research
because older adults with depression may require a more
advanced treatment program than standard CBT-I alone
[35, 61, 62]. The original CBT for depression manual [4]
briefly discussed strategies to address symptoms of insom-
nia, most notably cognitively reframing negative predictions
about poor sleep and increasing meaningful activities dur-
ing the day. Integrating CBT for insomnia and depression
(CBT-I-D) could be particularly helpful when staying in
bed becomes an escape from the distress associated with
the depression itself [61, 62]. This increased desire to sleep
and withdraw from daily activities is likely to increase the
attempts to sleep, which in turn, can exacerbate cognitive
and somatic arousal and interfere with overall sleep qual-
ity [62]. Thus working simultaneously on both issues
could create an increased therapeutic effect and further
enhance sleep and mood outcomes. To date, no study
has examined whether an advanced form of CBT-I-D
produces greater reductions in insomnia and depres-
sion severity compared to CBT-I alone.
Aims and hypotheses
The purpose of this study is to present a protocol that
has been designed to evaluate whether CBT-I is effective
for older adults with comorbid insomnia and depression
in community mental health settings. This study aims to
investigate whether there are significant differences be-
tween the three conditions (CBT-I, CBT-I-D, and PCG),
with a particular focus on whether CBT-I-D produces
greater reductions in insomnia and depression severity
compared to CBT-I. The final aim of the study is to
qualitatively explore the participants’ experience of
taking part in the trial. This feedback will play an import-
ant role in improving future studies that explore the de-
livery of CBT-I for older adults with complex conditions.
There are two central hypotheses in this study. First, it
is expected that participants who are randomised to the
CBT-I condition will report a significant reduction in
insomnia severity compared to participants who are
randomised to the PCG condition at post (week 8) and
follow-up (week 20) assessments. Second, it is hypothe-
sised that participants who are randomised to the CBT-
I-D condition will report greater reductions in insomnia
and depression severity compared to participants who
are randomised to the CBT-I and PCG conditions at
post- and follow-up assessments.
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Methods/Design
Trial design
This trial will follow the International CONSORT (Con-
solidated Standards of Reporting Trials) guidelines and
evaluate conditions using a randomised control trial
(RCT) design [56]. Participants who are eligible for the
trial will be randomly allocated to one of three conditions:
CBT-I, CBT-I-D, or PCG. Outcomes will be assessed at
pre-intervention (week 0), post-intervention (week 8), and
3-month follow-up (week 20). Figure 1 illustrates the
study’s design and expected participant flow chart.
Participants
We are recruiting participants through an aged persons’
community mental health services in regional catchments
of Victoria, Australia. A highly inclusive approach will be
used to maximise participation and increase generalisabil-
ity. Participants will be eligible for the trial if they meet
the following criteria: aged 65 years or above, been re-
ferred to an aged persons’ mental health service, current
Comorbid Insomnia Disorder [1], and past and/or current
Major Depressive Disorder [1].
Participants who meet criteria for Comorbid Insomnia
Disorder will report (a) dissatisfaction with their sleep asso-
ciated with either difficulty initiating sleep, difficulty main-
taining sleep, or early morning awakening with the inability
to return to sleep; (b) causing significant impairment of
functioning; (c) at least 3 nights per week; and (d) is present
for at least 3 months. Participants who meet criteria for
past and/or current Major Depressive Disorder will report
(a) depressed mood or lack of interest/pleasure consistently
over a 2-week period; (b) five or more of the following
symptoms, which include change of appetite/weight, sleep
disturbance, psychomotor agitation/retardation, loss of
energy, worthlessness/guilt, indecisiveness, or suicide
ideation; and (c) the symptoms cause significant func-
tional impairment.
Participants will be excluded if they are cognitively
impaired (Mini Mental State Exam score below 24;
[21]); in a crisis stage of mental illness (for example,
exhibiting psychotic features or demonstrating active
suicidal intent/plan); on unstable doses of medication
(this means eligible participants will need to be on
the same doses of their prescribed medications for at
least 1 month prior to commencing the intervention);
currently participating in Electro-Convulsive Therapy
(ECT); or currently participating in CBT with another
psychotherapist.
Assessment
Potential participants will be provided with a trial invita-
tion via the aged persons’ mental health service staff. In-
terested participants will be asked to sign an informed
consent document prior to commencing the eligibility
assessment. Once consent is obtained, participants will
be invited to participate in a preliminary insomnia
screen. This screen will correspond with the Diagnostic
and Statistical Manual for Mental Disorders 5th edition
(DSM-V) criteria for Comorbid Insomnia Disorder [1]
and follow Morin and Benca’s [40] insomnia assessment
guidelines. Participants meeting comorbid insomnia cri-
teria will then be invited to participate in a clinical inter-
view eligibility assessment.
Demographic information will be collected, including
age, sex, relationship status, education level, income source,
accommodation type, religious beliefs, past occupation,
medical history, and medications. Participants will be asked
if they have been diagnosed with a sleep disorder, and if so,
their treatment (for example, CPAP) and perceived treat-
ment effectiveness. Participants will also be screened for
sleep apnea and other comorbid sleep conditions (for
example, restless legs) by administering the SLEEP-50
[65]. It is important to note that participants with co-
morbid medical, sleep, and psychiatric conditions will
be included in this trial.
The Mini International Neuropsychiatric Interview
(MINI 6.0; [58, 59]) will be administered to assess Major
Depressive Disorder (past/current episode) and other
high prevalence mental disorders. The MINI is a clinical
psychiatric diagnostic tool with structured ‘yes’ or ‘no’
responses, (for example, ‘Were you ever depressed or
down, most of the day, nearly every day, for two
weeks?’). The MINI is more efficient to administer com-
pared to other structured diagnostic instruments (for ex-
ample, SCID), taking approximately 15 to 30 minutes to
complete. The MINI corresponds with the DSM-IV diag-
nostic criteria, which is commonly applied in research
settings. The MINI has demonstrated inter-rater and
test-retest reliability and validity across diverse popula-
tions (for example, [58, 60]) including older adults [51].
Since the MINI was standardised on the DSM-IV, the
principal investigator updated the items for each disorder
to be consistent with the DSM-V criteria.
The Mini-Mental State Examination (MMSE; [21]) will
be used to screen for possible cognitive impairment. The
MMSE contains 30 items that assesses a range of cogni-
tive functions, such as orientation, short-term memory,
language, comprehension, attention and calculation [21].
Total scores on the MMSE range from 0 to 30. Partici-
pants with scores of 23 or below are considered likely to
have a cognitive impairment [21]. The MMSE has shown
high levels of reliability and validity; for instance, studies
have reported internal consistencies of up to Cronbach’s
α = .90, and test-retest reliabilities over a 24-hour period
above r = .85 [36]. In addition, Mitchell [36] found the
MMSE demonstrated adequate sensitivity (71.1 % to
85.1 %) and specificity (81.3 % to 95.6 %) across a range
of settings.
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Measures
Once the eligible clinical assessment has been completed,
eligible participants will be asked to complete a self-report
questionnaire package at pre-treatment (week 0) to collect
baseline outcome measures. Participants will also be asked
to complete the outcome measures at post-intervention
(week 8) and 3-month follow-up (week 20). Participants
will be financially reimbursed ($20) each time they
complete the questionnaire pack ($60 total) to acknow-
ledge this additional time dedicated toward the study.
Table 1 shows the schedule and frequency of the assess-
ments during the trial.
The Insomnia Severity Index (ISI; [38]) is a self-report
instrument measuring the participant’s perception of his
or her level of insomnia. The ISI assesses the subjective
symptoms and consequences of insomnia, as well as the
degree of concerns or distress caused by those difficul-
ties during the previous two weeks. The ISI comprises
seven items assessing the severity of sleep-onset and
sleep maintenance difficulties (both nocturnal and early
Fig. 1 Study design and participant flow chart. Note: ECT = Electroconvulsive Therapy, CBT = Cognitive Behaviour Therapy, CBT-I = CBT for
Insomnia, CBT-I-D = CBT for Insomnia and Depression, PCG = Psychoeducation Control Group
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morning awakenings), satisfaction with current sleep
pattern, interference with daily functioning, ability to no-
tice the level of sleep impairment, and degree of distress
or concern caused by the sleep problem. Each item is
rated on a five-point scale (0 = none, to 4 = very). Total
scores range from 0 to 28, with higher scores represent-
ing more severe levels of insomnia. Total scores of 0 to
7 indicate no clinically significant insomnia; scores of 8
to 14 indicate sub-threshold insomnia; and scores of 15
to 28 indicate moderate to severe levels of insomnia.
Bastein et al. [2] conducted a psychometric study of
the ISI among older adults. It was found that the
mean item-total correlations were r = .56 at pre-treatment,
r = .69 at post-treatment, and r = .72 at follow-up. The in-
ternal reliability coefficients remained stable from .76 at
baseline to .78 at follow-up. Bastein et al. concluded that
the ISI was a useful clinical tool for screening insomnia se-
verity among older adults or as an outcome measure in in-
somnia treatment research.
The Consensus Sleep Diary (CSD; [12]) allows individ-
uals to record information about their nightly sleep pat-
tern. A recent panel of international sleep experts [12]
developed the CSD as the current standardised sleep
diary measure for insomnia research. The CSD contains
nine items that were considered by the expert panel to
represent the most critical sleep parameters (for ex-
ample, ‘What time did you get into bed?’). The CSD was
formatted so that 1 week of nightly sleep data could be
recorded on a single diary page. The CSD instructions
included general information, such as what to do if the
respondent misses recording on a particular day, and an
item-by-item instruction guide to enhance the likelihood
of correct item interpretation. Additional instructions in-
dicate that all items should be completed in the morning
within 1 hour of getting out of bed. Previous research
(for example, [52]) has reported that sleep diaries were
accurate when compared to polysomnographic data
(kappa = .87; sensitivity = 92.3 %; specificity, 95.6 %). Re-
searchers agree that having individuals prospectively
self-monitor their sleep with a sleep diary is a useful psy-
chometric tool for insomnia assessment and for examin-
ing treatment effects (for example, [10]).
The SLEEP-50 [65] is designed to measure the intensity
of an individual’s subjective sleep complaints on a range of
sleep conditions, including sleep apnea, insomnia, narco-
lepsy, restless legs, circadian rhythms, sleepwalking, night-
mares, other factors influencing sleep, and functioning
impairment. The SLEEP-50 is scored on a four-point
Likert scale from 1 ‘not at all’ to 4 ‘very much’. An ex-
ample sleep apnea item includes ‘I am told that I hold my
breath when sleeping’. The SLEEP-50 is considered a reli-
able and valid screening tool for comorbid sleep condi-
tions, Spoormaker et al. reporting a 3-week test-retest
reliability of r = .78 and Cronbach’s α of .85.
The Dysfunctional Beliefs and Attitudes About Sleep
10-Item Scale (DBAS-10; [19]) measures the intensity of
maladaptive beliefs about sleep (for example ‘When I
have trouble getting to sleep, I should stay in bed and
try harder’). Espie et al. redeveloped this measure into a
shorter version of 10 items from the original 30-item
Table 1 Assessments and administration frequency
Concept Measure Instrument Conditions
Week Week Week
0 8 20
Primary outcomes Insomnia severity ISI x x x
Depression severity GDS x x x
Secondary outcomes Sleep quality CSD x x x
Diagnosis MINI 6.0 x x x
Anxiety GAI-SF x x x
Hopelessness BHS x x x
Beliefs about sleep DBAS-10 x x x
Sleep conditions SLEEP-50 x x x
Health EQ-5D-3 L x x x
Eligibility Insomnia diagnosis DSM-V Insomnia Screen x x x
Cognitive screen MMSE x - -
Moderators Demographics Demographic Information x - -
Treatment Expectations TCI x - -
Feedback Reflective Focus Group - x -
Note: ISI Insomnia Severity Index, CSD Consensus Sleep Diary, GDS Geriatric Depression Scale, MINI Mini International Neuropsychiatric Interview, GAI-SF Geriatric
Anxiety Inventory Short Form, BHS Beck Hopelessness Scale, DBAS-10 Dysfunctional Beliefs and Attitudes About Sleep 10-Item Scale, EQ-5D-3 L EuroQol Health
Scale, MMSE Mini Mental State Examination, TCI Treatment Credibility Index
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DBAS scale of Morin [38]. Participants complete each
question using a 10-cm visual analogue scale, anchored
with strongly disagree and strongly agree. Added to-
gether, the 10 item responses provide the final DBAS
score. Total scores range from 0 to 100, with higher
scores representing more rigid or stronger levels of
dysfunctional beliefs and attitudes about sleep. The
DBAS-10 was has been found be a reliable measure of
dysfunctional beliefs about sleep among older adults
(Cronbach’s α = 0.88; [55]).
The Geriatric Depression Scale (GDS; [74]) is a 30-
item clinician-rated questionnaire used to assess depres-
sion severity specifically for older adults. Participants are
asked to respond ‘yes/no’ to each item, for example,
‘Over the past week have you felt that your life has been
empty?’ Possible scores range from 0 to 30, with higher
scores indicating the presence of more depressive symp-
tomatology. A total score of 0 to 9 indicates normal
levels of depression, 10 to 19 indicates mild to moderate
levels of depression, and 20 to 30 indicates severe de-
pression [74]. Yesavage et al. reported that the GDS
had a high degree of internal consistency (Cronbach’s
α = .94) and weekly test-retest reliability (r = .85), and
displayed strong correlations with other well-validated
depression measures (for example, Hamilton Rating
Scale for Depression, r = .83).
The Geriatric Anxiety Inventory Short Form (GAI-SF;
[11]) is a five-item version of the original 20-item Geriat-
ric Anxiety Inventory [46], which assesses anxiety sever-
ity among older adults. Respondents answer yes/no to
the five items, for example, ‘I worry a lot of the time’. A
score of three or more indicates probable anxiety dis-
order. At this cut off, sensitivity was 75 %, and specificity
was 87 %. Internal consistency was also found to be
high, Cronbach’s α at .81 [11].
The Beck Hopelessness Scale (BHS; [5]) is a self-report
instrument, which entails 20 true/false statements de-
signed to assess the degree to which an individual holds
over negative beliefs about the future from the previous
week. For example, a participant that answers ‘True’ to
the follow question, ‘My future seems dark to me’, would
score 1 point and represent a pessimistic response. Each
of the 20 statements is scored 0 or 1, with the total being
calculated by summing the pessimistic responses for the
20 items. The total BHS score ranges from 0 to 20, with
higher scores reflecting higher levels of hopelessness. A
total score ranging from 0 to 3 identifies minimal hope-
lessness, from 4 to 8 identifies mild hopelessness, from 9
to 14 identifies moderate hopelessness, and greater than
14 identifies severe hopelessness. The BHS has been
used widely among older adult community samples (for
example, [68]). Test-retest reliability of the BHS over a
6-week period ranged from r = .66 to r = .69, and internal
consistency was high, Cronbach’s α = .93 [7].
The EQ-5D-3 L scale [69] measures perceived health
status. It comprises five items measuring mobility, self-
care, usual activities, pain, and mood. Each item is rated
on a three-point Likert scale (1 = no problems, 2 = some
problems, 3 = extreme problems). The EQ-5D-3 L also
contains an additional item, which asks respondents to rate
their overall current health level using a visual analogue
scale from ‘0 =worst imaginable health’ to ‘100 = best im-
aginable health’. The EQ-5D-3 L has been validated across
several populations and countries (for example, [24]) and is
considered an appropriate outcome measure of health
status [9].
The Treatment Credibility Index (TCI; [15]) measures
treatment credibility and expectancy for use in clinical
trials. It involves six items that cover two factors:
thinking-based credibility (for example, ‘How logical does
the therapy offered to you seem?’) and feeling-based ex-
pectancy (for example, ‘How much improvement in your
symptoms do you really feel will occur?’). The TCI dem-
onstrated high internal consistency (Cronbach’s α = .85)
and good test-retest reliability (r = .82 for expectancy and
r = .75 for credibility).
Outcome assessors
The post- and follow-up outcome assessments will be
conducted by provisional and general registered psychol-
ogists who are on clinical placement or employed with
the aged persons’ mental health services. The independ-
ent assessors will have no therapeutic involvement with
the intervention group they are testing. They will also be
blinded to the condition they are evaluating. The asses-
sors will receive training and supervision by the princi-
pal investigator throughout the trial.
Primary outcomes
The primary outcomes being assessed are insomnia and
depression severity. Participants’ level of insomnia (ISI;
[38]) and depression (GDS; [74]) will be assessed using
validated self-report questionnaires.
Secondary outcomes
The secondary outcomes being assessed are sleep quality
(CSD; [12]), mental health diagnosis (MINI 6.0; [58]), anx-
iety (GAI-SF; [11]), hopelessness (BHS; [4]), beliefs/atti-
tudes about sleep (DBAS-10; [38]), comorbid sleep
conditions (SLEEP-50; [65]), and health status (EQ-5D-3 L;
[69]).
Interventions
Cognitive Behaviour Therapy for Insomnia (CBT-I)
CBT-I is a structured, time limited, multi-component
program that includes a combination of educational,
cognitive, and behavioural interventions (for example,
[3, 34, 38, 40]). The main objective of CBT-I is to change
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factors that perpetuate insomnia, including behavioural
factors (poor sleep habits and irregular sleep schedules),
psychological factors (unrealistic expectations about
sleep and unhelpful sleep beliefs), and physiological fac-
tors (somatic tension and cognitive hyperarousal). The
CBT-I program will closely follow Morin’s CBT-I treat-
ment guidelines (for example, [3, 38–40, 42]), and will
also acknowledge the works from Lichstein (for example,
[29]) and Rybarczyk (for example, [53]) in treating co-
morbid insomnia.
Participants assigned to the CBT-I condition will at-
tend eight weekly 60 to 90 minute sessions, which will
include small groups comprising five to six participants.
Group therapy was chosen instead of individual therapy
because working in groups is more cost-effective and
time-efficient [27]. This is particularly important for re-
gionally based community mental health settings where
resources can be limited [54]. Group therapy also creates
an opportunity to increase participants’ sense of belong-
ing, provide peer-to-peer support and motivation [27].
The format and delivery of treatment will follow a clear
CBT session structure [29, 40]. Information handouts
and homework worksheets for each CBT-I intervention
will be provided and kept in a daily workbook. The prin-
cipal investigator of this study carefully designed these
worksheets to be easily legible and workable for older
adults. Participants will be educated about the strong rela-
tionship between homework compliance, group connect-
edness, attendance, and treatment effect [18, 26]. Each
participant will also be encouraged to have a supportive
person (for example, family member or friend) to assist
their homework compliance during the trial [26].
The behavioural sleep interventions of CBT-I will
be introduced in the first four sessions of the
program and include stimulus control/restriction,
sleep hygiene, and relaxation skills [38, 40, 42]. The
cognitive sleep interventions in CBT-I will be covered
in the latter half of the program, which includes cog-
nitive restructuring. During this second half of the
program, considerable discussion will be devoted to
relapse prevention and maintaining progress [40, 42].
Table 2 illustrates a summary of the session interven-
tions for each condition.
Cognitive Behaviour Therapy for Insomnia and Depression
(CBT-I-D)
Participants who are assigned to the CBT-I-D group will
complete the same program as the participants assigned
to the CBT-I group (for example, eight sessions of CBT-I);
however, the CBT-I-D group will include an additional
three CBT strategies to address comorbid depression
(behavioural activation, cognitive reframing for depres-
sion, and affirmations).
The first additional intervention in this group will in-
clude behavioural activation. Behavioural activation, or
activity scheduling, is a common intervention included
in CBT for depression, which aims to increase an indi-
vidual’s level of activity, socialisation, and sense of
achievement/pleasure [6, 73, 75]. This involves setting
behavioural goals and planned activities, and keeping a
daily activity schedule to explore how the participants’
feel before and after an activity. These behavioural ex-
periments will be regularly discussed and monitored
during the program.
The second and third additional elements of CBT-I-D
involve including a broader focus on cognitive reframing
and positive affirmations. In addition to reframing sleep-
related dysfunctional beliefs, participants in this group
Table 2 Summary of session interventions
Session CBT-I CBT-I-D PCG
1 Introduction Introduction Introduction
2 Stimulus control Stimulus control Insomnia
Sleep restriction Sleep restriction
3 Sleep hygiene Sleep hygiene Sleep health
Behavioural activation
4 Relaxation Relaxation Sleep and mood
Behavioural activation
5 Relaxation Relaxation Sleep and mood
Cognitive reframing (insomnia) Cognitive reframing (insomnia)
6 Cognitive reframing (insomnia) Cognitive reframing (insomnia/depression) Beliefs about sleep
7 Cognitive reframing (insomnia) Cognitive reframing (depression) Beliefs about sleep
Affirmations
8 Relapse prevention Affirmations Summary
Relapse prevention
Note: CBT-I Cognitive Behaviour Therapy for Insomnia, CBT-I-D Cognitive Behaviour Therapy for Insomnia and Depression, PCG Psychoeducation Control Group
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will also learn to reframe important negative thoughts
related to their depression (for example, [4, 6, 73]). This
will be achieved through additional thought records and
positive affirmation hope cards introduced during the
latter four sessions of the program.
Control
Psycho-Education Control Group (PCG)
Participants assigned to the PCG will also attend eight
weekly, 60 to 90 minute sessions, in small groups com-
prising five to six participants. The content of these ses-
sions will include psychoeducation about sleep, insomnia,
and depression, with no active cognitive or behavioural
change strategies (for example, instructions, guidelines,
homework tasks, relapse prevention). This group will take
a more supportive approach rather than a structured CBT
format. Morin et al. [41] and Mogenthaler et al. [44] re-
ported that providing only psycho-education is an appro-
priate control condition in insomnia treatment research.
Therapists
The therapists who co-facilitate the groups will be provi-
sionally registered psychologists who are completing
their final clinical psychology placement within the aged
persons’ mental health services. The groups will be co-
facilitated due to the heterogeneous and complex nature
of this sample. The therapists will receive daily training
and clinical supervision throughout the trial by the prin-
cipal investigator.
Focus groups
At the end of the final session (Session 8) of each condi-
tion, participants will be invited to participate in a focus
group to reflect on their experiences from participating
in the trial. They will be asked eight questions (for ex-
ample, ‘What specific strategy was most helpful during
the program?’ that have been designed to inform future
CBT programs in this field. The focus groups will be
conducted by the principal investigator and audio re-
corded for qualitative statistical analysis. The principal
investigator will approach the focus groups in a non-
judgemental and curious manner, encouraging open
discussion and reflection rather than challenging the
participants’ responses [50].
Randomisation
The randomisation allocation process of participants to
treatment groups will comply with CONSORT guidelines
(for example, [37]). A block/cluster randomisation design
utilising random permuted blocks with randomised block
sizes will be implemented to randomly allocate each par-
ticipant group to one of three conditions throughout the
trial. Block randomisation is commonly used in small- to
moderate-sized RCTs to ensure that approximately equal
numbers of participant groups in the clustered context are
allocated to each condition [67]. The computer-generated
random allocations will be generated by an independent
researcher at Federation University Australia and will be
stored on a password-protected computer back-up to a se-
cure university file server. Random allocation will occur
after the pre-treatment assessments have been completed
to ensure eligibility has been met. Each successive random
allocation will be communicated to the principal investi-
gator only when five to six eligible participants are ready
to commence a group. Participants will be unaware of the
study’s hypotheses or which group they have been ran-
domly allocated. The co-therapists will not be blinded to
the treatment conditions.
Sample size calculation
Statistical power analysis was based on an examination
of treatment-time interactions in a repeated measures
analysis of covariance (RMANCOVA) of the ISI measure
[38], with adjustment for confounders. We specified an
initial value of 18 points in the adjusted mean of the ISI
score at pre-intervention [22]; a mean reduction of 10
points from pre- to post-intervention for the CBT-I
treatment [22]; and a target value of two points differ-
ence between the pre-post changes for each of the three
treatment conditions (that is, -8, −10, and −12 points,
respectively) [43], with no further change at follow-up
[43], and assuming a ‘within-treatments’ SD of 3.4 points
[22]. This resulted in an effect size of 0.23. Under the as-
sumptions of constant correlation over time (sphericity),
with an estimated magnitude of r = 0.6 based on re-
ported test-retest reliabilities of 0.79 [14] and 0.86 [76],
and allowance for a design effect [16] of 1.07 due to
clustering of participants within treatment groups (based
on an assumed cluster size of five and an intra-class cor-
relation of 0.017, [22]), with a significance level of 5 %
and 80 % power, the required sample size calculated
using GPower software [20] is N = 35 (33 × 1.07). Main-
taining the same specifications, but focusing solely on
the CBT-I and CBT-I-D conditions, the specific target
difference of two points between the pre-post changes
for these two particular treatments corresponds to an ef-
fect size of 0.13. In order to have 80 % power to detect
this particular difference in a post hoc pairwise compari-
son, the required sample size is increased to N = 85
(78 × 1.07).
With regard to the GDS measure [74], Secker and
Brown [57] reported pre- and post-intervention means
of 7.0 and 4.4 in a treatment group, and 5.8 and 4.7 in a
control group, a difference of 1.5 units [(7.0 - 4.4 = 2.6) -
(5.8 - 4.7 = 1.1)] in the pre- and post-change, and an
average within-treatment SD of 3.5. Replacing the values
of 2.0 and 3.4 in the ISI analysis with 1.5 and 3.5 results
in effect sizes of 0.16 with respect to comparisons across
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the three conditions and 0.10 with respect to compari-
sons between the two conditions. This leads to required
sample sizes of N = 68 with respect to comparison of
mean GDS across the three conditions, and N = 150 with
respect to comparison of mean GDS between two of the
conditions. Because this is larger than N = 85 from the
ISI projection, N = 150 becomes our target sample size,
which equates to 50 participants or 10 groups per
condition.
Statistical analyses
Data will be entered, screened, and analysed using SPSS
Version 21 [25]. A RMANCOVA will be implemented to
explore differences between the conditions over time,
and calculate effect sizes to investigate the treatment ef-
fect. An intention-to-treat methodology will be applied
via multiple imputation. The qualitative data obtained
from the focus groups will be analysed according to the
Interpretative Phenomenological Analysis (IPA) method
(for example, [50, 63]). This will be achieved by tran-
scribing the data verbatim from audio recordings into
text. The text transcripts will be read several times to
extract emerging codes, which will then be transformed
into themes [50]. Themes are likely to identify both
something of importance to the participants, and also
convey a meaning of their reflection [63]. These themes
will form the basis for the qualitative results. Direct quotes
from the participants will also be reported to highlight the
thematic findings [63].
Ethics approval and trial registration
This trial will be conducted in accordance with the eth-
ical guidelines outlined in the National Statement on
Ethical Conduct in Human Research [45]. Ethics ap-
proval for this project has been granted by the Feder-
ation University Australia Human Research Ethics
Committee (E-14-042), the Latrobe Regional Hospital
Human Research Ethics Committee (2014-02-LNR), and
the Peninsula Health Human Research Ethics Commit-
tee (HREC-15-PH-4). The trial has also been registered
with the Australian New Zealand Clinical Trial Registry,
ACTRN: 12615000067572.
Discussion
This paper describes the study protocol for the develop-
ment and evaluation of a CBT program for older adults
with comorbid insomnia and depression. The results
from this trial will represent a significant step forward in
this field and assist in advancing CBT-I for older adults
receiving mental health services for depression. Several
important clinical implications could result from this
project.
One of the primary aims is to evaluate whether CBT-I
is effective among a complex sample of older adults with
comorbid insomnia and depression in a community
mental health setting. We predict that CBT-I will be
more effective at reducing insomnia severity compared
to the PCG. If this hypothesis is supported, it will dem-
onstrate that CBT-I is helpful at reducing insomnia se-
verity for older adults with depression in a community
mental health setting. This evidence will add to a growing
research base that suggests CBT-I needs to be considered
as a treatment option for individuals with comorbid in-
somnia [30, 66, 71].
Since previous research has suggested that comorbid
insomnia is often misunderstood and inadequately
treated [18, 40, 62], education and training play a vital
role to address this disparity between research and clin-
ical practice. This could involve providing workshops to
mental health practitioners to raise their awareness of
addressing comorbid insomnia during the assessment,
case conceptualisation, and treatment planning phases.
To ensure older adults with comorbid insomnia have ac-
cess to this form of psychological treatment, mental
health services could also consider training a therapist
on their multidisciplinary team in CBT-I, or at least
source an external CBT sleep specialist as a referral op-
tion. These implications could potentially improve thera-
peutic outcomes for older adults receiving mental health
services by ensuring clinicians are better equipped to ad-
dress comorbid insomnia.
This project also plans to explore whether improving
an older adult’s sleep pattern with CBT-I has an associ-
ated positive impact on their mood. Recent preliminary
evidence suggests CBT-I can have a positive effect of de-
pression levels [28, 32, 72]; however, these studies have
substantial methodological limitations that restrict the
generalisability of the results. Consequently, this study
aims to test whether CBT-I generates greater reductions
in depressive severity compared to a PCG. If the results
indicate that CBT-I is more effective at improving de-
pression compared to the control condition, aged psy-
chiatric services could consider adding CBT-I as a
regular treatment option for their clients presenting with
comorbid insomnia and depression.
A unique feature of this trial involves testing an advanced
form of CBT-I that includes additional strategies to address
comorbid depression among older adults. Although recent
studies (for example, [71]) have suggested that specifically
designed CBT-I programs may produce better overall out-
comes for targeted populations (for example, older adults
with comorbid insomnia and depression), no study
has tested whether an advanced CBT-I-D program is more
effective than a standard CBT-I program. The results fol-
lowing this specific investigation could highlight that CBT-
I is sufficient to address both insomnia and depression or
indicate CBT-I-D is clinically indicated to better treat these
conditions simultaneously. This result could guide future
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CBT-I treatment programs in relation to either broadening
or lessening the scope of treatment.
Finally, we are interested in studying the participants’
experiences from taking part in a CBT trial for insomnia
and depression. The information gained from a mixed
methods design will provide an opportunity to gather
rich, personal data through older adults that can either
confirm or disconfirm the questionnaire outcome mea-
sures [13, 33]. This can open new avenues of explanation
for particular findings that traditional quantitative mea-
sures cannot detect [47]. For example, results from the
reflective focus groups may indicate participants benefit-
ted from specific CBT strategies that would not be re-
vealed through quantitative data [33]. In addition,
participants may provide innovative feedback that is par-
ticularly relevant to the delivery of CBT-I among this
complex aged population. Therefore, it is expected that
the qualitative findings from this project will enhance
the direction of future research in this field.
Despite the important implications that may result
from this study protocol, the project will likely include
limitations. First, no physiological measure of sleep (for
example, polysomnography) will be assessed to cross-
validate the clinical interview and self-report data. This
means that the assessments throughout the trial will be
reliant on subjective measures from the participants and
researchers, as opposed to objective biological data.
Since no standardised clinical diagnostic instrument has
been established yet for the DSM-V, the authors updated
existing DSM-IV diagnostic instruments (for example,
MINI 6.0) to be consistent with the DSM-V diagnostic
criteria. Finally, participant recruitment and retention
rates could be negatively affected due to this population
likely experiencing stronger symptoms of tiredness,
hopelessness, and amotivation. Hence, recruiting partici-
pants and keeping them engaged throughout the program
will likely create significant challenges. Notwithstanding
these limitations, the results following this study protocol
will likely contribute important knowledge that improves
case formulation and treatment planning for older adults
with comorbid insomnia and depression.
Trial status
Recruitment began in August 2014 and will continue
until June 2016.
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